Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CRIS
- CUSIP: 23126910
- Web: www.curis.com
Capitalization:- Market Cap: $257.29 million
- Outstanding Shares: 143,878,000
Average Prices:- 50 Day Moving Avg: $1.81
- 200 Day Moving Avg: $2.12
- 52 Week Range: $1.47 - $3.72
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.93
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $8.31 million
- Price / Sales: 27.18
- Book Value: $0.06 per share
- Price / Book: 26.17
Profitability:- EBIDTA: ($48,510,000.00)
- Net Margins: -836.18%
- Return on Equity: -236.43%
- Return on Assets: -88.44%
Debt:- Debt-to-Equity Ratio: 4.33%
- Current Ratio: 3.72%
- Quick Ratio: 3.72%
Misc:- Average Volume: 580,589 shs.
- Beta: 1.9
- Short Ratio: 9.59
Frequently Asked Questions for Curis (NASDAQ:CRIS)
What is Curis' stock symbol?
Curis trades on the NASDAQ under the ticker symbol "CRIS."
How were Curis' earnings last quarter?
Curis, Inc. (NASDAQ:CRIS) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.10) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The firm earned $2.10 million during the quarter, compared to analysts' expectations of $2.08 million. Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The company's revenue for the quarter was up 23.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.09) earnings per share. View Curis' Earnings History.
When will Curis make its next earnings announcement?
Where is Curis' stock going? Where will Curis' stock price be in 2017?
3 equities research analysts have issued 1-year price objectives for Curis' stock. Their predictions range from $6.00 to $7.00. On average, they expect Curis' share price to reach $6.50 in the next year. View Analyst Ratings for Curis.
What are analysts saying about Curis stock?
Here are some recent quotes from research analysts about Curis stock:
- 1. According to Zacks Investment Research, "Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. " (7/17/2017)
- 2. Cowen and Company analysts commented, "In our view, recent underperformance of CRIS shares is not reflective of the continued." (5/5/2017)
Who are some of Curis' key competitors?
Some companies that are related to Curis include Kala Pharmaceuticals (KALA), Adamas Pharmaceuticals (ADMS), Voyager Therapeutics (VYGR), Mesoblast Limited (MESO), Cara Therapeutics (CARA), Agenus (AGEN), Arbutus Biopharma Corporation (ABUS), Celldex Therapeutics (CLDX), Corvus Pharmaceuticals (CRVS), Idera Pharmaceuticals (IDRA), NewLink Genetics Corporation (NLNK), Concert Pharmaceuticals (CNCE), Novavax (NVAX), Puretech Health PLC (PRTC), Protagonist Therapeutics (PTGX), Codexis (CDXS), Nabriva Therapeutics AG (NBRV) and Horizon Discovery Group PLC (HZD).
Who are Curis' key executives?
Curis' management team includes the folowing people:
- James R. McNab Jr., Independent Chairman of the Board
- Ali Fattaey Ph.D., President, Chief Executive Officer, Director
- James E. Dentzer, Chief Financial Officer, Chief Administrative Officer
- Mani Mohindru Ph.D., Senior Vice President, Chief Strategy Officer
- David Tuck M.D., Chief Medical Officer
- Lori A. Kunkel M.D., Director
- Martyn D. Greenacre, Independent Director
- Kenneth I. Kaitin Ph.D., Independent Director
- Robert E. Martell M.D., Ph.D., Independent Director
- Kenneth J. Pienta M.D., Independent Director
Who owns Curis stock?
Curis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include First Eagle Investment Management LLC (16.70%), FMR LLC (10.45%), Vanguard Group Inc. (3.45%), State Street Corp (1.29%), Northern Trust Corp (0.93%) and Royal Bank of Canada (0.66%). Company insiders that own Curis stock include Daniel R Passeri, Discovery Technologie Aurigene, James R Mcnab, Kenneth I Kaitin and Martyn D Greenacre. View Institutional Ownership Trends for Curis.
Who sold Curis stock? Who is selling Curis stock?
Curis' stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., TIAA CREF Investment Management LLC, Teachers Advisors LLC, FMR LLC, California State Teachers Retirement System, Janney Montgomery Scott LLC, ProShare Advisors LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Curis.
Who bought Curis stock? Who is buying Curis stock?
Curis' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., BB&T Securities LLC, State of Wisconsin Investment Board, Alliancebernstein L.P., OxFORD Asset Management LLP, Northern Trust Corp and Royal Bank of Canada. View Insider Buying and Selling for Curis.
How do I buy Curis stock?
Shares of Curis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Curis' stock price today?
One share of Curis stock can currently be purchased for approximately $1.57.
MarketBeat Community Rating for Curis (NASDAQ CRIS)MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Curis (NASDAQ:CRIS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $6.50 (314.01% upside) |
Analysts' Ratings History for Curis (NASDAQ:CRIS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/15/2017 | Cowen and Company | Reiterated Rating | Buy | | N/A |  |
| 3/11/2017 | FBR & Co | Set Price Target | Buy | $6.00 | Low | |
| 10/12/2016 | Royal Bank Of Canada | Set Price Target | Buy | $7.00 | N/A | |
| 9/7/2016 | Robert W. Baird | Reiterated Rating | Outperform | $7.00 | N/A | |
| 3/1/2016 | SunTrust Banks, Inc. | Initiated Coverage | Buy | $3.00 | N/A | |
| 2/29/2016 | Roth Capital | Reiterated Rating | Buy | $5.00 | N/A | |
(Data available from 9/26/2015 forward)
Earnings History for Curis (NASDAQ:CRIS)Earnings History by Quarter for Curis (NASDAQ CRIS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($0.09) | | | | | N/A | |
| 8/3/2017 | Q2 2017 | ($0.09) | ($0.10) | $2.08 million | $2.10 million | View | Listen | |
| 5/4/2017 | Q1 17 | ($0.09) | ($0.11) | $1.98 million | $2.13 million | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.10) | ($0.08) | $1.97 million | $2.40 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.10) | ($0.21) | $1.84 million | $1.80 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.09) | ($0.09) | $2.05 million | $1.70 million | View | Listen | |
| 5/9/2016 | Q116 | ($0.08) | ($0.07) | $2.30 million | $1.70 million | View | Listen | |
| 2/29/2016 | Q415 | ($0.12) | ($0.10) | $2.98 million | $2.10 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.08) | ($0.04) | $2.82 million | $2.00 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.06) | ($0.06) | $3.50 million | $2.10 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.06) | ($0.07) | $2.27 million | $1.17 million | View | N/A | |
| 2/24/2015 | Q4 14 | ($0.07) | ($0.07) | $2.69 million | $2.00 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.05) | ($0.06) | $4.13 million | $1.80 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.06) | ($0.02) | $3.46 million | $4.80 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.07) | ($0.06) | $1.88 million | $1.30 million | View | N/A | |
| 2/20/2014 | Q413 | ($0.08) | ($0.05) | $1.59 million | $1.52 million | View | N/A | |
| 11/5/2013 | Q313 | ($0.01) | ($0.02) | $6.44 million | $7.20 million | View | N/A | |
| 8/5/2013 | Q2 2013 | ($0.05) | ($0.02) | $4.43 million | $5.40 million | View | N/A | |
| 4/30/2013 | Q1 2013 | ($0.05) | ($0.06) | $3.86 million | $0.90 million | View | N/A | |
| 2/20/2013 | Q4 2012 | ($0.08) | ($0.15) | $2.07 million | $1.69 million | View | N/A | |
| 11/6/2012 | Q312 | ($0.08) | ($0.04) | $1.01 million | $0.60 million | View | N/A | |
| 8/2/2012 | | ($0.05) | ($0.04) | | | View | N/A | |
| 5/8/2012 | | $0.02 | $0.03 | | | View | N/A | |
| 10/27/2011 | | ($0.07) | ($0.05) | | | View | N/A | |
| 7/28/2011 | | ($0.07) | ($0.06) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Curis (NASDAQ:CRIS)2017 EPS Consensus Estimate: ($0.28)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.08) | ($0.08) | ($0.08) |
| Q2 2017 | 1 | ($0.07) | ($0.07) | ($0.07) |
| Q3 2017 | 1 | ($0.07) | ($0.07) | ($0.07) |
| Q4 2017 | 1 | ($0.06) | ($0.06) | ($0.06) |
(Data provided by Zacks Investment Research)
Dividend History for Curis (NASDAQ:CRIS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Curis (NASDAQ:CRIS)Insider Ownership Percentage: 4.07%
Institutional Ownership Percentage: 44.72%
Insider Trades by Quarter for Curis (NASDAQ:CRIS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/5/2017 | James R Mcnab | Director | Sell | 76,276 | $2.04 | $155,603.04 | |
| 5/2/2017 | James R Mcnab | Director | Sell | 116,708 | $2.38 | $277,765.04 | |
| 4/27/2017 | James R Mcnab | Director | Sell | 146,694 | $2.61 | $382,871.34 | |
| 4/24/2017 | James R Mcnab | Director | Sell | 110,322 | $2.59 | $285,733.98 | |
| 9/7/2016 | Discovery Technologie Aurigene | Major Shareholder | Buy | 10,208,333 | $2.40 | $24,499,999.20 | |
| 5/27/2016 | Martyn D Greenacre | Director | Sell | 15,000 | $1.69 | $25,350.00 | |
| 5/26/2016 | Kenneth I Kaitin | Director | Sell | 15,000 | $1.76 | $26,400.00 | |
| 12/30/2015 | Daniel R. Passeri | Director | Sell | 14,400 | $3.01 | $43,344.00 | |
| 12/29/2015 | Daniel R. Passeri | Director | Sell | 11,200 | $2.91 | $32,592.00 | |
| 12/28/2015 | Daniel R. Passeri | Director | Sell | 13,600 | $2.85 | $38,760.00 | |
| 12/23/2015 | Daniel R. Passeri | Director | Sell | 48,900 | $2.78 | $135,942.00 | |
| 12/21/2015 | Daniel R. Passeri | Director | Sell | 289,000 | $2.99 | $864,110.00 | |
| 8/27/2014 | Ali Ph.D. Fattaey | CEO | Buy | 62,890 | $1.60 | $100,624.00 | |
| 12/11/2013 | Ali Ph.D. Fattaey | COO | Buy | 3,000 | $2.52 | $7,560.00 | |
| 11/12/2013 | Michael Gray | CFO | Buy | 10,000 | $2.86 | $28,600.00 | |
| 11/8/2013 | Kenneth Pienta | Director | Buy | 20,000 | $2.95 | $59,000.00 | |
| 8/16/2013 | James Mcnab | Director | Sell | 50,000 | $4.00 | $200,000.00 | |
| 12/6/2012 | Daniel R Passeri | CEO | Buy | 25,000 | $3.03 | $75,750.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Curis (NASDAQ:CRIS)
Latest Headlines for Curis (NASDAQ:CRIS)
| Source: |
|
| Date | Headline |
|---|
 | Curis to Present at the Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 23 at 2:38 AM |
 | Curis to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 22 at 4:32 PM |
 | Comparing Curis (CRIS) & Idera Pharmaceuticals (IDRA)
www.americanbankingnews.com - September 21 at 4:48 AM |
| Curis, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.17 Million
www.americanbankingnews.com - September 21 at 3:18 AM |
| Curis, Inc. (CRIS) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - September 19 at 4:24 PM |
| Why Curis Inc (CRIS) Could Be A Buy
finance.yahoo.com - September 18 at 10:31 PM |
| Curis, Inc. (CRIS) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - September 16 at 7:08 PM |
| Curis Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
www.globenewswire.com - September 15 at 10:58 PM |
| Curis Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 14 at 6:20 PM |
 | Curis prices stock offering but doesn't disclose price
seekingalpha.com - September 14 at 9:25 AM |
| 3 Things In Biotech You Should Learn Today: September 13, 2017
seekingalpha.com - September 14 at 5:11 AM |
| Curis Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - September 13 at 6:48 PM |
| Curis Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 13 at 6:47 PM |
| Aurigene, a Wholly Owned Subsidiary of Dr. Reddy’s, and Curis Announce CA-170 Program Update Following Data Presented at ESMO 2017
finance.yahoo.com - September 12 at 6:13 PM |
 | Curis (CRIS) & Aurigene Report CA-170 Program Update Following ... - StreetInsider.com
www.streetinsider.com - September 11 at 6:11 PM |
| Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017
finance.yahoo.com - September 11 at 6:11 PM |
| Curis (CRIS) Presents At Baird's 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 7 at 5:39 PM |
| Curis to Present at the Baird 2017 Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 6 at 10:33 PM |
| Curis to Present at the Baird 2017 Global Healthcare Conference
finance.yahoo.com - September 6 at 5:32 PM |
| Curis, Inc. (CRIS) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 6 at 2:28 AM |
| ETFs with exposure to Curis, Inc. : September 6, 2017
finance.yahoo.com - September 6 at 12:06 AM |
 | Do Options Traders Know Something About Curis (CRIS) Stock We Don't?
www.nasdaq.com - September 5 at 7:06 PM |
| Do Options Traders Know Something About Curis (CRIS) Stock We Don't?
finance.yahoo.com - September 5 at 7:06 PM |
| Curis, Inc. (CRIS) Lifted to Hold at ValuEngine
www.americanbankingnews.com - September 3 at 4:32 PM |
| Curis (CRIS) Announces CA-170 Poster Presentation at ESMO
www.streetinsider.com - September 1 at 10:52 PM |
| Curis (CRIS) Announces CA-170 Poster Presentation at ESMO - StreetInsider.com
www.streetinsider.com - August 31 at 10:25 PM |
| Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress - GlobeNewswire (press release)
globenewswire.com - August 31 at 5:24 PM |
| Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress
finance.yahoo.com - August 31 at 5:24 PM |
| ETFs with exposure to Curis, Inc. : August 25, 2017
finance.yahoo.com - August 25 at 9:01 PM |
| Curis, Inc. (CRIS) Upgraded by BidaskClub to Sell
www.americanbankingnews.com - August 20 at 1:54 PM |
| Curis, Inc. :CRIS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
finance.yahoo.com - August 16 at 5:54 PM |
| Curis (CRIS) and GTx (GTXI) Head to Head Analysis
www.americanbankingnews.com - August 15 at 6:08 PM |
| -$0.09 EPS Expected for Curis, Inc. (NASDAQ:CRIS) This Quarter
www.americanbankingnews.com - August 13 at 6:10 PM |
| Curis, Inc. (NASDAQ:CRIS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 12 at 2:32 AM |
 | EARNINGS SUMMARY: Details of Curis Inc Q2 Earnings Report
www.rttnews.com - August 4 at 5:47 PM |
| Edited Transcript of CRIS earnings conference call or presentation 3-Aug-17 12:30pm GMT
finance.yahoo.com - August 4 at 5:47 PM |
| Curis, Inc. (CRIS) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - August 3 at 8:32 PM |
 | Here's Why Curis, Inc. Dropped as Much as 14.5% This Morning - Motley Fool
www.fool.com - August 3 at 4:28 PM |
| Curis Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 4:28 PM |
| Here's Why Curis, Inc. Dropped as Much as 14.5% This Morning
finance.yahoo.com - August 3 at 4:28 PM |
| Curis reports 2Q loss
finance.yahoo.com - August 3 at 4:28 PM |
| Cara Therapeutics Appoints Mani Mohindru As CFO
www.rttnews.com - August 1 at 6:14 PM |
| Analysts Anticipate Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.06 Million
www.americanbankingnews.com - July 28 at 5:21 PM |
| Curis to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017 - GlobeNewswire (press release)
globenewswire.com - July 27 at 10:49 PM |
| Curis to Release Second Quarter 2017 Financial Results and Hold ... - Nasdaq
www.nasdaq.com - July 26 at 6:04 PM |
| Curis to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017
finance.yahoo.com - July 26 at 6:04 PM |
| Zacks: Brokerages Anticipate Curis, Inc. (CRIS) to Announce -$0.09 EPS
www.americanbankingnews.com - July 26 at 12:29 PM |
| Curis, Inc. (CRIS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 18 at 1:53 PM |
| Curis, Inc. (CRIS) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 17 at 8:26 PM |
 | Technical Insights on Biotech Stocks -- Curis, OvaScience, Regulus Therapeutics, and Vanda Pharma
www.bizjournals.com - July 12 at 11:14 PM |
Curis (CRIS) Chart for Tuesday, September, 26, 2017
